Chronic kidney disease (CKD) is a common1 yet widely underrecognized and potentially deadly condition2,3 and is estimated to affect more than 160 million people with type 2 diabetes (T2D) worldwide.4,5,6 CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced.7,8
Early detection and intervention are essential to slow the progression of CKD in your T2D patients.9 The KDIGO, ADA, and EASD guidelines recommend testing both eGFR and UACR at least once a year in patients with CKD and T2D.9,10,11
Hear from leading experts below on how outcomes can be improved for patients living with CKD and T2D, alongside insights from their experience and best practices.
Professor Peter Rossing
Head of Complications Research at Steno Diabetes Center Copenhagen, Denmark
Professor Carolyn Lam
Senior Consultant of the National Heart Centre, Singapore
Primary Care Physician
Professor Richard Hobbs
Nuffield Professor of Primary Care Health Sciences, UK
Professor Christoph Wanner
Professor of Medicine and Head of the Division of Nephrology University Hospital of Würzburg, Germany
Up to 40% of patients with T2D will develop CKD.12,13,14 L earn more about why early detection and intervention are essential to slow the progression of CKD in your T2D patients and protect them from CV events.
A panel discussion on chronic kidney disease in T2D with four key opinion leaders.
Professor Carolyn Lam (Senior Consultant of the National Heart Centre, Singapore) and Professor Richard Hobbs (Nuffield Professor of Primary Care Health Sciences,UK) discuss the close link between CKD and T2D.
The panel discusses what comprises a collaborative approach for patients with CKD in T2D that need multidisciplinary care.
The panel discusses the key challenges when clinicians discuss kidney health with patients with CKD and T2D.
The panel discusses the different roles of health care providers to support the management of patients with CKD and T2D as a broader team.